Transoral Robotic Surgery and the Unknown Primary: A Cost‐Effectiveness Analysis
J. Kenneth Byrd(Augusta University), Umamaheswar Duvvuri(City University of New York), William G. Albergotti(University of Pittsburgh Medical Center), Seungwon W. Kim(University of Pittsburgh Medical Center), John R. de Almeida(Princess Margaret Cancer Centre), Robert L. Ferris(University of Pittsburgh), Jonas T. Johnson(University of Pittsburgh), Kara S. Davis(University of Pittsburgh), Kenneth J. Smith(National Hospital for Neurology and Neurosurgery)
Cited by 53
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590